Avenue Therapeutics Inc. (NASDAQ: ATXI) is -89.28% lower on its value in year-to-date trading and has touched a low of $1.39 and a high of $26.85 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ATXI stock was last observed hovering at around $1.43 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $1.46, the stock is -25.05% and -60.78% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.26 million and changing 2.10% at the moment leaves the stock -71.59% off its SMA200. ATXI registered -91.75% loss for a year compared to 6-month loss of -61.69%.
The stock witnessed a -47.29% gain in the last 1 month and extending the period to 3 months gives it a -66.20%, and is -18.44% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.60% over the week and 13.02% over the month.
Distance from 52-week low is 5.07% and -94.56% from its 52-week high.
Avenue Therapeutics Inc. (ATXI) Analyst Forecasts
The EPS is expected to grow by 29.70% this year
Avenue Therapeutics Inc. (ATXI) Top Institutional Holders
The shares outstanding are 4.77M, and float is at 4.37M with Short Float at 4.86%.
Avenue Therapeutics Inc. (ATXI) Insider Activity
A total of 1 insider transactions have happened at Avenue Therapeutics Inc. (ATXI) in the last six months, with sales accounting for 1 and purchases happening 0 times. The most recent transaction is an insider sale by InvaGen Pharmaceuticals, Inc., the company’s 10% Owner. SEC filings show that InvaGen Pharmaceuticals, Inc. sold 388,888 shares of the company’s common stock on Oct 11 at a price of $7.71 per share for a total of $3.0 million. Following the sale, the insider now owns 0.0 shares.
Avenue Therapeutics Inc. (ATXI): Who are the competitors?
The company’s main competitors (and peers) include Omeros Corporation (OMER) that is -72.99% lower over the past 12 months.